Biogen

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,500

Employees7,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,500

Employees7,500

BIIB Key Statistics

Market cap

29.09B

Market cap29.09B

Price-Earnings ratio

20.72

Price-Earnings ratio20.72

Dividend yield

—

Dividend yield—

Average volume

1.26M

Average volume1.26M

High today

$199.72

High today$199.72

Low today

$194.11

Low today$194.11

Open price

$194.11

Open price$194.11

Volume

887.84K

Volume887.84K

52 Week high

$205.97

52 Week high$205.97

52 Week low

$121.05

52 Week low$121.05

Stock Snapshot

The current Biogen(BIIB) stock price is $196.97, with a market capitalization of 29.09B. The stock trades at a price-to-earnings (P/E) ratio of 20.72.

During the trading session on 2026-05-27, Biogen(BIIB) shares reached a daily high of $199.72 and a low of $194.11. At a current price of $196.97, the stock is +1.5% higher than the low and still -1.4% under the high.

Trading volume for Biogen(BIIB) stock has reached 887.84K, versus its average volume of 1.26M.

The stock's 52-week range extends from a low of $121.05 to a high of $205.97.

BIIB News

MarketWatch 2h

Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch

...

TipRanks 9h

Biogen price target raised to $227 from $222 at RBC Capital

RBC Capital raised the firm’s price target on Biogen (BIIB) to $227 from $222 and keeps an Outperform rating on the shares. The firm is citing findings from its...

Seeking Alpha 11h

Biogen faces Italian antitrust probe over rivalry with Sandoz for MS drugs

The Italian Competition Authority on Wednesday announced an investigation into Biogen (BIIB) over alleged abuse of market dominance to sell a multiple sclerosis...

Analyst ratings

55%

of 38 ratings

Buy

55.3%

Hold

39.5%

Sell

5.3%

More BIIB News

TipRanks 5d

Denali, Biogen Halt Parkinson’s Trial After Efficacy Failure

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 6d

Biogen and Denali’s Parkinson’s candidate did not meet Phase 2b endpoints

Biogen (BIIB) and Denali Therapeutics (DNLI) announced topline results from the Phase 2b LUMA study evaluating BIIB122, an investigational small molecule inhibi...

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.